IDXX 153.00 Idexx Laboratories $IDXX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
IDXX 153.00 Idexx Laboratories $IDXX Hit a 52 week high of 153.89 Closing the day 09:44 at 153.00 +0.12 +0.08% With a day low of 152.75 and a total volume of 13,002.

IDXX Recent Posts: http://investorshangout.com/IDEXX-Laboratorie...DXX-54421/

IDXX Idexx Laboratories Recent Headline News

Uptrend Call Working As Idexx Laboratories Stock Rises 24.1% (IDXX)
Comtex SmarTrend(R) - Wed Nov 12, 9:56AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 weeks, Idexx Laboratories has returned 24.07% as of today's recent price of $152.00.
IDXX: 152.54 (-0.34)

Trade-Ideas: Idexx Laboratories (IDXX) Is Today's Strong And Under The Radar Stock
at The Street - Tue Nov 11, 9:42AM CST
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.54 (-0.34)

SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 1.39% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:17PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $144.18 to a high of $147.67. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $146.00 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.54 (-0.34)

Idexx Laboratories Earnings Hindsight: Up 7.4% in Last 17 Days (IDXX)
Comtex SmarTrend(R) - Mon Nov 10, 1:31PM CST
17 days ago, on October 24th, 2014, Idexx Laboratories (NASDAQ:IDXX) reported its earnings. Analysts, on average, expected earnings of $0.86 per share on sales of $371.3 million. Idexx Laboratories actually reported earnings of $1.05 per share on sales of $383.5 million, beating EPS estimates by $0.19 and beating revenue estimates by $12.2 million. Since the company's report, shares of Idexx Laboratories have risen from $135.20 to $145.16, representing a gain of 7.4% in the past 17 days.
IDXX: 152.54 (-0.34)

Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 152.54 (-0.34)

Comparing America's 3 Largest Diagnostic Substances Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 03, 12:03PM CST

QDEL: 28.28 (-0.11), NEOG: 44.22 (-0.38), IDXX: 152.54 (-0.34)

Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 188.04 (+1.17), GE: 26.48 (-0.04), BMRN: 87.21 (+0.26), IDXX: 152.54 (-0.34), GSK: 45.70 (+0.08), NVS: 94.40 (+1.74)

IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 152.54 (-0.34)

IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.44 (+0.02), EW: 124.17 (+1.22), IDXX: 152.54 (-0.34), ANGO: 16.89 (-0.09)

Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.54 (-0.34)

IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 152.54 (-0.34)

Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.54 (-0.34)

IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:02PM CDT

IDXX: 152.54 (-0.34)

Idexx Q3 income up 14%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 10:00AM CDT

IDXX: 152.54 (-0.34)

Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 152.54 (-0.34)

IDEXX Laboratories beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:07AM CDT

IDXX: 152.54 (-0.34)

IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS" for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 152.54 (-0.34)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT

WYN: 79.81 (-0.26), SFE: 19.51 (-0.10), F: 15.01 (+0.43), OCR: 69.32 (+0.45), B: 37.44 (+0.09), SXC: 22.89 (-0.02), VTR: 69.14 (+0.79), UPS: 108.08 (-0.54), DLPH: 70.64 (+0.19), CHH: 53.09 (-0.02), LYB: 87.78 (-0.81), COG: 32.72 (-0.75), SHPG: 202.02 (+1.51), TCB: 15.95 (-0.07), AVY: 48.17 (+0.07), AAN: 27.47 (-0.13), MGLN: 61.35 (-0.28), STT: 76.09 (-1.36), FNFG: 7.77 (-0.01), IMGN: 10.10 (-0.02), EDU: 21.99 (+0.18), BMY: 57.83 (-0.78), DTE: 80.66 (-0.24), LEA: 93.05 (+0.62), MCO: 100.38 (+0.30), FLIR: 32.73 (-0.25), IMS: 24.69 (-0.01), LPNT: 64.20 (-0.36), ERIC: 12.06 (+0.25), PG: 89.26 (-0.22), IDXX: 152.54 (-0.34), WBC: 100.97 (-1.27), NDAQ: 43.81 (-0.22), CL: 68.65 (-0.05)

Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 152.54 (-0.34), ORCL: 40.50 (+0.36)

IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 152.54 (-0.34)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 92

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 158

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Spruce Point's Strong Sell Rating Casts Doubt on Construction Partners

Updated Category News Views 116

Spruce Point's Strong Sell Opinion on Construction Partners Inc Spruce Point Capital Management has recently issued a compelling report regarding Construction Partners Inc (NASDAQ: ROAD), a company recognized for its expertise in infrastructure and road construction. This report voices a strong sell recommendation, reflecting serious concerns over the company's current...

Continue Reading
Celebrating Excellence in Healthcare: Press Ganey's Honorees

Updated Category News Views 344

Celebrating the Executive Human Experience Award Winners Press Ganey, an industry leader dedicated to enhancing healthcare experiences, recently celebrated exceptional achievements in the field. During its annual conference, the Executive Human Experience Awards recognized extraordinary contributions from professionals and organizations that prioritize patient, consumer,...

Continue Reading
Commercial Vehicle Market Growth Driven by Technology Advancements

Updated Category News Views 122

Commercial Vehicle Market Growth and Projections The global commercial vehicle market is on an upward trajectory, with sales expected to reach 3.5 million units by 2025. The anticipated Year-over-Year (YoY) growth of 4.4% from 2024 highlights the increasing demand for medium and heavy commercial vehicles. This trend is being driven by several factors, including...

Continue Reading
Atos Receives Prestigious EcoVadis Platinum Medal Again

Updated Category News Views 195

Let’s not beat around the bush—Atos is doing something right in the sustainability game. They've bagged the EcoVadis Platinum Medal for five years running. Yep, that’s a serious flex in today’s corporate climate where ‘green’ isn’t just a buzzword; it’s almost an obligation if you want to stay relevant. The Metrics Behind Atos's Shine Scoring a...

Continue Reading
Power Metallic Mines Updates Shareholder Meeting Outcomes

Updated Category News Views 157

Power Metallic Mines Reports on AGSM Meeting Outcomes Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) expressed satisfaction with the voting outcomes from its Annual General and Special Meeting ("AGSM") that took place recently. The meeting gathered shareholders to discuss essential business items and elect members to the Board of...

Continue Reading